Blackmores Limited: How I got it wrong but why you don't want to buy in yet

Vitamins and supplements supplier Blackmores Limited (ASX: BKL) appears to have turned its business around

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's safe to say that vitamins and supplements supplier Blackmores Limited (ASX: BKL) has proved me wrong over the past year or so.

I'd virtually written the company off in a number of articles published in 2013 and 2014, as Australian and New Zealand sales stagnated, and I couldn't see growth in Asia filling the hole.

From 2011, when net profit was $27.3 million, the next three years produced earnings of $27.8m, $25.0m and $25.4 million. Clearly, Blackmores was struggling to generate growth.

Profit margins fell to their lowest levels since 2005 (as the chart below shows), despite revenues still rising. It seemed like the supermarket juggernauts Woolworths Limited (ASX: WOW) and Coles – owned by Wesfarmers Ltd (ASX:WES) were exerting their influence on Blackmores, much like they've done to other suppliers like Coca-Cola Amatil Ltd's (ASX: CCL) SPC Ardmona, Patties Foods Ltd (ASX: PFL) and a host of other producers.

Source: Company reports
Source: Company reports

But all that appears to have changed in the last year or so. In the six months to December 2014, the vitamin producer saw a net profit of $18.6 million, up 54% higher than the previous year, as revenues jumped 22%, driven by sales through pharmacies such as Chemist Warehouse.

The signs were there that Blackmores could generate strong growth previously. In 2013, the company grew revenues by 25%, but that didn't translate to net profit, which fell 10%, hit by a decline in profit margins. In October 2013, the company saw its first-quarter profit fall by 31% – with the company labelling the Australian retail market 'highly challenging'.

Those margins appear to be on the mend, rising strongly in the last half from 7.3% last financial year, to 9%. Incidentally, that's very close to Blackmores' long-term average profit margin of 8.5%.

So how has the company turned it around?

One only needs to take a closer look at management commentary around recent results to find that out.

In the 2014 annual report, chairman Marcus Blackmore wrote,

"The key growth indicators within our business may be modest, although I believe we have turned a corner and have promising prospects for the coming year."

He wasn't wrong about that.

The acquisition of Fit-BioCeuticals in July 2012 certainly has helped. The company primarily sells health products with higher dosages that can only be purchased on recommendation by doctors or naturopaths. BioCeuticals delivered $4.6 million in earnings before interest, tax, depreciation and amortisation (EBITDA) in 2011. In 2014, BioCeuticals delivered $6.8 million in earnings before interest and tax (EBIT), nearly 20% of group EBIT, before corporate costs. In the last half, the division delivered again, with a 17% increase in sales.

But the biggest gains have come from the Australian business thanks to strong pharmacy sales and growing demand for Blackmores' products from Chinese consumers. (Is this the making or strengthening of a competitive advantage – the Blackmores' brand?).

Sales into Asia are also rising, although Thailand appears to be a recalcitrant child.

Management also appear to have focused on improving margins through cost cutting, expense management and repaying debt – which has fallen from $87 million 2013 through to $63 million at the end of December 2014, with net debt at $36.7 million. Increasing benefits of scale through higher production runs are also improving fixed costs and adding to improved margins.

All in all, it means higher revenues and more cents in the dollar dropping through to the bottom line.

A juiced up price

There are a few problems, and the main one is the share price — currently around $77.50. Blackmores' shares have rocketed up more than 120% since the beginning of this year alone.

Based on estimates for net profit this financial year, Blackmores' shares are trading on a prospective P/E ratio of more than 30x earnings. The company's long-term average is around 16-17x.

Source: Company reports, Motley Fool calculations
Source: Company reports, Motley Fool calculations

 

That suggests that the market expects the vitamin maker to continue pumping out strong growth for at least the next few years.

If Blackmores can do that, then today's price might be justified. The problem is that the company might be unable to push its EBIT margins much higher, so earnings growth is unlikely to grow at such a fast clip in future.

Other issues include steadily falling returns on capital (ROCE), equity (ROE) and assets (ROA) — although I'll qualify that they are still impressive by market standards (ROE of 25%) – but it's something to watch.

Source: Company reports, Motley Fool calculations
Source: Company reports, Motley Fool calculations

I'll be keeping an eye on Blackmores. It's definitely one of the higher-quality companies on the ASX, but I'd like a cheaper price to buy in at.

Motley Fool contributor Mike King owns shares of Coca-Cola Amatil Limited and Woolworths Limited. You can follow Mike on Twitter @TMFKinga The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »